Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin
Research article published in Blood (2006)
Abstract
The antithrombotic efficacy of lepirudin in patients with heparin-induced thrombocytopenia (HIT) is compromised by an increased risk for bleeding. A retrospective observational analysis in 181 patients (median age, 67 years) with confirmed HIT treated in routine practice with lepirudin was performed to identify predictive factors for thrombotic and bleeding complications. Lepirudin was administered at a mean (+/- SD) dose of 0.06 +/- 0.04 mg/kg/h (compared with a recommended initial dose of 0.15 mg/kg/h). Mean activated partial thromboplastin time was greater than 1.5 times baseline value in 99.4% of patients. Median treatment duration was 7.7 days. Until discharge from the hospital, 13.8% and 20.4% of patients experienced a thrombotic or a major bleeding event, respectively. On multivariate analysis, mean lepirudin dose was not a significant predictive factor for thrombosis. In contrast, mean lepirudin dose greater than 0.07 mg/kg/h, long duration of lepirudin treatment, and moderate to severe renal impairment were significant positive factors for major bleeding. Overall, these results suggest that the recommended dose of lepirudin in patients with HIT is too high; the use of reduced doses may be safer with regard to bleeding risk and does not compromise antithrombotic efficacy.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
The antithrombotic efficacy of lepirudin in patients with heparin-induced thrombocytopenia (HIT) is compromised by an increased risk for bleeding.
Por qué esto importa para la hirudoterapia
Este estudio observacional retrospectivo analizó a 181 pacientes con trombocitopenia inducida por heparina (TIH) confirmada que fueron tratados con lepirudina en la práctica clínica rutinaria. El estudio identificó que la dosis inicial recomendada de lepirudina de 0,15 mg/kg/h pareció demasiado alta, ya que las dosis medias superiores a 0,07 mg/kg/h, la duración prolongada del tratamiento y la insuficiencia renal moderada a grave fueron predictores significativos de sangrado mayor. Las dosis reducidas no comprometieron la eficacia antitrombótica, lo que sugiere una estrategia de dosificación más segura. Si bien la lepirudina proporciona una conexión farmacéutica directa con las terapias anticoagulantes, el resumen no aporta contexto sobre sus orígenes biológicos ni su relación con la terapia viva con sanguijuelas y el secretoma crudo de la sanguijuela, lo que limita su relevancia estrictamente a la dosificación clínica de este fármaco específico.
Citación
Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin
Tardy B et al. · Blood, 2006
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026